ASX:VR1
One to watch
September 28, 2023
Vection Technologies
:
Meeting with CEO Gianmarco Biagi

Venn Brown sat down with Gianmarco Biagi, CEO of Vection Technologies, to discuss immersive integrated Extended Reality (IntegratedXR) technologies, it's partnerships with Accenture, Cisco, NTT DATA and DXC Technology, and the expanding adoption of mixed reality and AI.

Thanks for your time today, Gianmarco. To start with, can you give us a brief overview of Vection Technologies?

Vection Technologies is a technology company focused on the industrial and professional sectors. We specialise in immersive integrated Extended Reality (IntegratedXR) technologies tailored for industry and government applications.

We operate five proprietary and patented platforms across Italy, the United States, India, the United Arab Emirates, and Australia. These platforms have earned us recognition as a trusted partner for some of the world’s largest tier-one companies.

We have established international collaborations with industry leaders such as Cisco, NTT DATA, Accenture, and DXC Technology. Despite our relatively short four-year presence in the market, these collaborations position us as a global reference in the field. As you’re aware, we’re listed on the ASX, but we’ve also just started trading on the over-the-counter (OTC) market in the United States.

Can you break down your products and the industries and customers you serve?

Vection Technologies provides comprehensive, integrated services in XR technologies. IntegratedXR stands for Integrated Extended Reality, encompassing virtual reality (VR), augmented reality (AR), mixed reality (MR), artificial intelligence, remote assistance, and other ICT  related services. We offer the full suite of products and all related services, including software, hardware, training, and integration services tailored to our clients’ systems. Our offerings also extend to specialised platforms like AI-powered kiosks designed for applications such as repair and maintenance. This integrated approach forms the core of our IntegratedXR services.

Vection Technologies has a suite of 5 VR and AR tools spanning design, collaboration, retail and more
Download full report
Other reports you may like
July 29, 2025
Earnings
Artrya
ASX:AYA
4Q25 results - SAPPHIRE progressing
Artray reported its 4Q25 cash flows yesterday. Operating cash flow was -$5.4 million with a step up in cash burn reducing operating cash flow. AYA is continuing to progress its SAPPHIRE study, with news on study partners expected in month or so. Costs in the quarter increased as AYA focused on submitting Silax Coronary Plaque for FDA approval (16th July 2025) and completing development of Silax Coronary Flow.
July 2, 2025
Industry & markets
Markets
Good, compared to what?
We review the relative performance of Australia’s leading indices and look at the long-term impact of underperformance. We also examine the fundamental limitation of the ASX Small Ordinaries index and why you should never passively invest in it.
June 16, 2025
Company update
Artrya
ASX:AYA
Salix Coronary Plaque submitted for FDA approval
Artrya announced today that it had submitted its application for approval by the FDA for its second product, Salix Coronary Plaque (SCP). The FDA aims to complete the approval process within 30 days, with the clock stopped if they request additional data. We also estimate that the 6-8 hospital groups Artrya are in discussions with about being part of its SAPPHIRE study could represent $4.5 billion in value.